<DOC>
	<DOCNO>NCT00257257</DOCNO>
	<brief_summary>Primary : Effect HbA1c 6 month drug-naive patient type 2 diabetes Secondary : Effect glucose , insulin , C-peptide , insulin resistance , body weight , HDL-cholesterol , triglyceride , blood pressure - Safety , tolerability</brief_summary>
	<brief_title>Study Evaluating Rimonabant Efficacy Drug-NAive DiabEtic Patients</brief_title>
	<detailed_description>The total duration study 6 1/2 month include screening period ( 14 day ) double-blind treatment period ( approximately 6 month ) patient mild hypocaloric diet ( 600 kcal/day deficit ) .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Rimonabant</mesh_term>
	<criteria>Male female patient age great equal 18 year . Diagnosis type 2 diabetes define WHO criteria least 2 month longer 3 year . Type 2 diabetes previously treat pharmacological agent . Note : ) insulin use accept within 6 month prior screen visit follow reason : prior use management gestational diabetes , shortterm ( less equal 1 month ) use maintain glycemic control hospitalization , medical procedure , intervention . b ) use oral antidiabetic agent accept within 6 month prior screen visit prescribe 4 month . HbA1C great equal 7 % less equal 10 % . Having sign informed consent form . General : Weight loss &gt; 5 kg within 3 month prior screen visit . Pregnancy lactation . Absence medically approve contraceptive method female childbearing potential . Marijuana hashish user . Administration investigational drug within 30 day prior screen visit . Previous participation rimonabant study . Presence history allergic reaction intolerance multiple drug . Presence condition ( e.g. , geographic , social ) Investigator feel would restrict limit patient 's participation duration study . Related endocrine metabolic disorder : Presence clinically significant endocrine disease accord Investigator . Note : euthyroid patient replacement therapy include dosage thyroxine stable least 3 month prior screen visit . Fasting Cpeptide &lt; 1.0 ng/mL . Related disorder : Presence severe medical psychological condition opinion Investigator would compromise patient 's safety successful participation study . Presence history cancer within past five year exception adequately treat localized basal cell skin cancer situ uterine cervical cancer . Related laboratory finding : Positive test hepatitis B surface antigen and/or hepatitis C antibody . Abnormal TSH level ( TSH &gt; ULN &lt; LLN ) . Hemoglobin &lt; 11 g/dL and/or neutrophil &lt; 1,500/mm3 and/or platelet &lt; 100,000/mm3 . Positive urine pregnancy test . Positive urine test marijuana hashish metabolite . Related previous concomitant medication : Oral antidiabetic agent except within 6 month prior screen visit prescribe 4 month . Insulin except within 6 month prior screen visit management gestational diabetes shortterm use maintain glycemic control hospitalization , medical procedure , intervention . Drugs affect weight ( e.g. , sibutramine , orlistat , herbal preparation , etc ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>Type 2 diabetes mellitus</keyword>
</DOC>